These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21077899)

  • 1. A quantitative comparison of 5-aminolaevulinic acid- and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy.
    Valentine RM; Ibbotson SH; Brown CT; Wood K; Moseley H
    Photochem Photobiol; 2011; 87(1):242-9. PubMed ID: 21077899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
    Tyrrell JS; Campbell SM; Curnow A
    Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?
    Ibbotson SH; Valentine R; Hearn R
    Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):272-3. PubMed ID: 22971196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
    Blake E; Allen J; Thorn C; Shore A; Curnow A
    Lasers Med Sci; 2013 May; 28(3):997-1005. PubMed ID: 22926533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
    Mikolajewska P; Iani V; Juzeniene A; Moan J
    Br J Dermatol; 2009 Nov; 161(5):1173-9. PubMed ID: 19785604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methyl aminolevulinate: actinic keratoses and Bowen's disease.
    Morton CA
    Dermatol Clin; 2007 Jan; 25(1):81-7. PubMed ID: 17126745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
    Choudry K; Brooke RC; Farrar W; Rhodes LE
    Br J Dermatol; 2003 Jul; 149(1):124-30. PubMed ID: 12890205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
    Fai D; Arpaia N; Romano I; Vestita M; Cassano N; Vena GA
    G Ital Dermatol Venereol; 2009 Jun; 144(3):281-5. PubMed ID: 19528909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The France-PDT study: a national prospective observational cohort survey on the use of methyl-aminolevulinate photodynamic therapy in France, with up to 6-month follow-up.
    Farhi D; Bedane C; Savary J; Basset-Seguin N
    Eur J Dermatol; 2013; 23(1):68-76. PubMed ID: 23400280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Bowen's disease with photodynamic therapy. Observational study in 171 patients with 5-aminolaevulinic acid (BF-200 ALA) and methyl aminolaevulinate (MAL).
    Alique-García S; Alique D; Company-Quiroga J; Sánchez A; Núñez AH; Borbujo J
    Photodiagnosis Photodyn Ther; 2019 Dec; 28():192-194. PubMed ID: 31398515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy.
    Britton JE; Goulden V; Stables G; Stringer M; Sheehan-Dare R
    Br J Dermatol; 2005 Oct; 153(4):780-4. PubMed ID: 16181460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence diagnosis and photodynamic therapy for Bowen's disease treatment.
    Truchuelo MT; Pérez B; Fernández-Guarino M; Moreno C; Jaén-Olasolo P
    J Eur Acad Dermatol Venereol; 2014 Jan; 28(1):86-93. PubMed ID: 23331846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy.
    Stables GI; Stringer MR; Robinson DJ; Ash DV
    Br J Dermatol; 1997 Jun; 136(6):957-60. PubMed ID: 9217836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.
    Tyrrell J; Campbell S; Curnow A
    Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):232-8. PubMed ID: 21112545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer.
    de Haas ER; de Vijlder HC; Sterenborg HJ; Neumann HA; Robinson DJ
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):426-30. PubMed ID: 18031503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
    Aguilar M; de Troya M; Martin L; Benítez N; González M
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin.
    Kulyk O; Ibbotson SH; Moseley H; Valentine RM; Samuel ID
    Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):630-9. PubMed ID: 26467274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate.
    de Bruijn HS; Meijers C; van der Ploeg-van den Heuvel A; Sterenborg HJ; Robinson DJ
    J Photochem Photobiol B; 2008 Aug; 92(2):91-7. PubMed ID: 18571933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.
    Tarstedt M; Gillstedt M; Wennberg Larkö AM; Paoli J
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):420-3. PubMed ID: 26841041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methyl aminolevulinate-based photodynamic therapy of Bowen´s disease: Observational study of 21 lesions.
    Gómez C; Cobos M; Alberdi E
    Photodiagnosis Photodyn Ther; 2019 Jun; 26():295-299. PubMed ID: 30986539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.